论文部分内容阅读
目的探讨IDA-FLAG方案治疗复发难治性白血病的疗效及临床分析。方法 2010年1月至2012年1月期间,我院诊治的80例复发难治性白血病患者,随机将其分为对照组(FLAG方案治疗)和观察组(IDA-FLAG方案治疗),每组各40例,对两组的临床疗效、不良反应,以及半年内的复发情况,进行观察和比较。结果与对照组相比,观察组的缓解率明显升高,半年内复发率明显降低,P<0.05,有统计学意义;与对照组相比,观察组不良反应发生率没有明显改变,P>0.05,没有统计学意义。结论对于复发难治性白血病患者,IDA-FLAG方案疗效显著,并且复发率低,值得临床推广。
Objective To investigate the efficacy and clinical analysis of IDA-FLAG regimen in the treatment of recurrent refractory leukemia. Methods From January 2010 to January 2012, 80 patients with recurrent refractory leukemia treated in our hospital were randomly divided into control group (FLAG regimen) and observation group (IDA-FLAG regimen), and each group Each 40 cases, the clinical efficacy, adverse reactions, as well as the recurrence within six months, were observed and compared. Results Compared with the control group, the remission rate of the observation group was significantly increased, and the recurrence rate was significantly reduced within six months (P <0.05), and there was no significant difference in the incidence of adverse reactions between the observation group and the control group (P> 0.05, no statistical significance. Conclusions The IDA-FLAG regimen has significant curative effect and low recurrence rate in patients with recurrent refractory leukemia, which is worthy of clinical promotion.